Latest Neuroendocrine tumor Stories
Research Presented at the Society of Gynecologic Oncology 2015 Annual Meeting Suggest Treatment Options Based on Biomarker Profile May Result in Improved Outcomes IRVING, Texas, March
-- Lexicon eligible for an additional $5 million in up-front and pre-commercial milestone payments for Canadian rights, plus royalties and sales milestones under original agreement --
Two studies presented at ENDO 2015 contribute to growing body of knowledge about acromegaly treatment NEWTON, Mass. and JERUSALEM, March 5, 2015 /PRNewswire/ -- Chiasma, Inc., a U.S.
NEWTON, Mass. and JERUSALEM, Feb. 27, 2015 /PRNewswire/ -- Chiasma, Inc., a U.S.
BURLINGAME, Calif., Jan.
Somatuline® is the first and only antitumor therapy demonstrating a statistically significant progression-free survival benefit in a combined population of patients with gastrointestinal
- Results show 94% of patients made lifestyle modifications as a result of their NET, including changes to diet, work, physical activities and social life(1) EAST HANOVER, N.J., Nov.
Presentations at 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology Point to Potential Strategies for Treatment of Small Cell, Non-small Cell, and Neuroendocrine Lung Cancers
-- Telotristat etiprate, a Phase 3 compound for the treatment of carcinoid syndrome PARIS and THE WOODLANDS, Texas, Oct.
- Afinitor led to an unprecedented median overall survival of 44 months, which represents a clinically meaningful while not statistically significant improvement(1) EAST HANOVER,